OBJECTIVES The aim of the present study was to evaluate the clinical value of the pretreatment serum testosterone (T) level as a potential predictor of prostate cancer risk in screening for prostate cancer. MATERIALS AND METHODS The subjects were 420 patients suspected of having prostate cancer who underwent prostate biopsy, and whose pretreatment T levels were recorded. We checked for associ...

negative impact on quality of life [2-5]. Serum Prostate Specific Antigen (PSA) is a globally used screening tool for carcinoma prostate, based on which prostate biopsy largely recommended when PSA value exceeds 4 ng/ mL [6]. PSA blood level variation had been studied with respect to numerous factors including age, race, prostate volume (PV), androgen level, body mass index (BMI), creatinine, l...

The significance of prostatic specific antigen (PSA) was investigated in the subjects examined by the mass screening for prostate cancer from 1985 to 1990. All subjects was examined by digital rectal examination (DRE) and with prostatic acid phosphatase (PAP) and the subjects in whom prostate cancer (Pca) was suspected from abnormal DRE and/or elevated PAP were recommended to receive the second...

Indications of prostate biopsy are high serum prostate specific antigen (PSA) value and or abnormal digital rectal examination (DRE) findings. Although serum PSA value of 4 ng/ml is the most commonly used threshold for recommending prostate biopsy, significant proportion of men harbor prostate cancer even when their serum PSA values are less than 4.0 ng/ml. Therefore present study was designed ...

Objective This study was undertaken to determine the likelihood of having serum total prostate specific antigen (PSA) levels ≥4.0 ng/mL and ≥10.0 ng/mL among a cohort of non-obese and obese Nigerian men with lower urinary tract symptoms (LUTS). Methods This was a prospective cross-sectional survey among men who presented with benign prostatic hypertrophy to the urology clinic of the Ekiti Sta...

conclusions results showed that whereas knowledge by itself cannot guarantee men’s participation in prostate cancer screenings, perceived barriers can play an important role in discouraging men from cancer screening participation. therefore, designing programs to address these barriers is very important. results the most common barriers to screening for prostate cancer were a lack of knowledge ...

Introduction Serum prostate-specific antigen (PSA) is of paramount importance as a diagnostic tool for the detection, staging, and monitoring of patients with prostate cancer. Because PSA is organ but not disease specific, it has certain limitations as a screening test for prostate cancer. After radical prostatectomy (RP), however, PSA is an excellent tumor marker with a high sensitivity and sp...

Primary urothelial carcinoma (UC) of the prostate is rare and accounts for only 0.7-2.8% of all prostate cancers. Unlike conventional adenocarcinoma of the prostate, UC does not express prostate-specific antigen (PSA) which can make diagnosis challenging due to both unexpected serum PSA levels and immunohistochemical profiles. We report the case of a 66 year-old man who was eventually diagnosed...

Antiandrogen withdrawal syndrome (AWS) is a well-established phenomenon in prostate cancer treated with combined androgen blockade (CAB). AWS is generally defined as subjective and/or objective improvement following discontinuation of an antiandrogen. However, the duration of the AWS response is usually limited. In addition, a complete response is quite rare. We herein present the case of a pat...